Stay updated on Alternative Schedule Study for VLA15 Clinical Trial
Sign up to get notified when there's something new on the Alternative Schedule Study for VLA15 Clinical Trial page.

Latest updates to the Alternative Schedule Study for VLA15 Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe page shows Revision: v3.4.2, replacing the previous v3.4.1 revision. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedUpdated Publications: added a Lancet Infect Dis 2024 paper on VLA15 dose optimization (revision v3.4.1) and removed its 2025 Erratum notice.SummaryDifference0.1%

- Check27 days agoChange DetectedGlossary toggle was added and labels were updated to reflect QC status and versioning (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) while the previous labels were removed (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). These are metadata/UI changes and do not affect the study content or results.SummaryDifference0.2%

- Check41 days agoChange DetectedRevision label on the page updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedA Lancet Infect Dis article on dose level optimization and vaccination schedule for VLA15 was added to the Publications section and subsequently removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a consolidated Locations section listing study sites in Connecticut and New York; removed the separate Connecticut Locations and New York Locations subsections, and updated page revision to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Alternative Schedule Study for VLA15 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alternative Schedule Study for VLA15 Clinical Trial page.